VYYRF - Voyageur Pharmaceuticals Ltd. Announces Two Health Canada Approvals and Issuance of Product Licenses for MultiX Ba; Radiographic Barium Contrast
(TheNewswire)
Calgary, Alberta - TheNewswire- April 5 th , 2021 -Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC :VYYRF ) (the "Company" or"Voyageur") is pleased to announce that it has receivedapproval from Health Canada (HC) for its product, MultiX bariumsulfate powder. MultiX is specifically designed for oralsuspension and indicated for use in single contrast radiographicexaminations of the esophagus, stomach, duodenum and small bowel tovisualize the gastrointestinal tract in adult and pediatric patients.Voyageur received 2 licenses for MultiX, one license for oralapplications and one license for rectal applications.
Voyageur is building a suite of barium radiographiccontrast media products and is working with our custom manufacturer,Alberta Veterinarian Laboratories (AVL), which company owns andoperates a brand new, multi-million dollar, state-of-the-art, GoodManufacturing Practice (GMP) drug manufacturing facility in Calgary,Alberta, Canada. Voyageur is rapidly moving to launch its sales intothe Canadian and international market places.
With three drugsnow approved and licensed by Health Canada and two more in the offing,Voyageur is shortly hiring highly-experienced radiographic contrast media professionals to our team tosupport:
-
- Scientific research anddevelopment to capitalize on opportunities to expand our high-qualitybarium and iodine contrast product portfolio into globalmarkets.
- International marketing, sales anddistribution.
Marketing and Sales Strategy2021
Approval timelines and high profit margin are thecriteria for Voyageur’s international sales strategy. Voyageur isactively analyzing international markets, where recognition ofVoyageur's Health Canada registrations is anticipated to assistVoyageur in obtaining licenses in an expeditious manner. Uponconclusion of our analysis, Voyageur will begin applying forregistration applications on a country-by-country basis,including FDA licenses in the USA.
Voyageur is working with AVL and is preparing to testour newly-formulated products under GMP and HC guidelines. Uponconclusion of testing, phase one marketing is expected to beginfollowed by sales and distribution to the Canadian, USA andinternational markets.
Fiscal 2020 Year End
Voyageur is also pleased to announce that the fiscal2020 year-end Management Discussion and Analysis and audited FinancialStatements have been filed and uploaded to SEDAR.
About Voyageur
Voyageur Pharmaceuticals Ltd. is Canadian publiccompany listed on the TSX Venture Exchange under the trading symbolVM. Voyageur is focused on the development of barite and iodine,Active Pharmaceutical Ingredient (API) minerals. The near-term focusis developing barium and iodine radio-contrast pharmaceuticalproducts. Voyageur’s goal is to initially generate near term positive cash flow fromoperations using third party GMP pharmaceutical manufacturers inCanada and internationally . Ultimately, Voyageur has plans to build all the requiredinfrastructure to become 100% self-sufficient with all manufacturing.Voyageur owns a 100% interest in three barium sulfate (barite)projects including two properties suitable in grade for the industrialbarite marketplace, with interests in a potentially high-grade iodine,lithium & bromine brine project located in Utah, USA.
Voyageur is moving forward with its business plan ofbecoming the only fully-integrated company in the radiographiccontrast medical field, by controlling all primary input costs underthe motto of: "From theEarth to the Bottle"
For Further Media Information or to set up aninterview, please contact:
Brent Willis
President & CEO
Ron Love
CFO
T 403.818.6086
E ronl@vpharma.ca
www.voyageurpharmaceuticals.ca
Forward Looking Information
This news release may contain certain forward-lookinginformation and statements, including, without limitation, statementspertaining to commercial launch of its products, including timing formanufacturing and sales of MultiX Ba, anticipated marketing and salesplans, and the expected timing thereof, the ability to obtain licensesin international jurisdictions, and to do so expeditiously based onexisting HC approvals, and the Company's ability to obtain necessaryapprovals from Health Canada for additional barium radiographiccontrast products. All statements included herein, other thanstatements of historical fact, are forward-looking information andsuch information involves various risks and uncertainties. There canbe no assurance that such information will prove to be accurate, andactual results and future events could differ materially from thoseanticipated in such information. A description of assumptions usedto develop such forward-looking information and a description of riskfactors that may cause actual results to differ materially fromforward-looking information can be found in the Company's disclosuredocuments on the SEDAR website at www.sedar.com. Voyageur does notundertake to update any forward-looking information except inaccordance with applicable securities laws.
Reader Advisory
Neither the TSXV nor its Regulation Services Provider(as that term is defined in the policies of the TSXV) acceptsresponsibility for the adequacy or accuracy of this newsrelease.
Copyright (c) 2021 TheNewswire - All rights reserved.